Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry
Authors:
- Robert C.G. MartinRobert C.G. Martin
- Allen CohnACAllen Cohn
- Bilal PiperdiBPBilal Piperdi
- Rebecca MiksadRMRebecca Miksad
- Jean-Francois GeschwindJGJean-Francois Geschwind
- Alec GoldenbergAGAlec Goldenberg
- Arun SanyalASArun Sanyal
- Ellen ZigmontEZEllen Zigmont
- Svetlana BabajanyanSBSvetlana Babajanyan
- Pamela ForemanPFPamela Foreman
- Parvez MantryPMParvez Mantry
- 1 April 2017
- journal article
- Published by Elsevier in The American Journal of Surgery
- Vol. 213 (4) , 688-695
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantationClinical Transplantation, 2013
- Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control studyJournal of Hepatology, 2013
- Sorafenib Treatment for Recurrent Hepatocellular Carcinoma After Liver TransplantationTransplantation Proceedings, 2012
- Sorafenib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation?Transplantation Proceedings, 2012
- Sorafenib for recurrence of hepatocellular carcinoma after liver transplantationDigestive and Liver Disease, 2012
- Hepatocellular carcinomaThe Lancet, 2012
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with CirrhosisNew England Journal of Medicine, 1996